CLASS III Drug recall · Reported 13 Sep 2023 · FDA Enforcement Report

Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg recalled by Esperion

Esperion is recalling Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, distributed nationwide in the US. The recall was initiated on 16 Aug 2023 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot# 1904872, Exp 1/31/2025; 1950377, Exp 6/30/2025
NDC72426-818
Quantity recalled45,240 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1143-2023
FDA event ID
92897
Recalling firm
Esperion, Ann Arbor, MI
Manufacturer
Esperion Therapeutics, Inc.
Classification
Class III
Status
Terminated
Recall initiated
16 Aug 2023
FDA classified
6 Sep 2023
Reported
13 Sep 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

16 Aug 2023Recall initiated by company
6 Sep 2023Classified by FDA+21 days
13 Sep 2023Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed dissolution specifications: below specification results at stability 12-month

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03

Where it was distributed

Nationwide USA

Nationwide

Questions about this recall

Why was it recalled?

Failed dissolution specifications: below specification results at stability 12-month

Which lots are affected?

Lot# 1904872, Exp 1/31/2025; 1950377, Exp 6/30/2025

Where was it sold?

Nationwide USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Esperion

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIINexlizet (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg recalledNexlizetEsperionPotency & AssayNationwide

Other Bempedoic Acid recalls

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIINexlizet (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg recalledNexlizetEsperionPotency & AssayNationwide